Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study
Authors' conclusion
In this real-world study, semaglutide treatment was not associated with a reduced risk of liver cirrhosis or hepatocellular carcinoma among adults with type 2 diabetes mellitus.
Study context
- Population
- Adults with T2D and no prior diagnosis of liver cirrhosis or hepatocellular carcinoma, large integrated healthcare organizationmatched cohort
- Participants
- 71,612 adults
- Exposure
- Semaglutide treatment vs matched controls
- Semaglutiden = 35,806
- Matched controlsn = 35,806reference
- Outcome
- Liver cirrhosis and hepatocellular carcinoma
- Follow-up
- Median 4628 days (cirrhosis) and 4090 days (HCC)
Methodological detailsmatched controls, electronic health records
- Matched controls
- Electronic health records
Main finding
As reported in the abstract
Each group vs matched controlsEstimate (95% CI)
Semaglutide
HR (liver cirrhosis) 1.3(0.98–1.77)
Semaglutide
HR (hepatocellular carcinoma) 0.6(0.21–1.51)
- Developed liver cirrhosis (all patients)
- 245
- Developed hepatocellular carcinoma (all patients)
- 21
Observational data: associations, not effects.
Original publication
Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study. Diabetes Obes Metab. Published 13 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →